Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT05353179
- Locations
- 🇨🇳
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China
A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 390
- Registration Number
- NCT05346952
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Cancer Hospital, Beijing, Beijing, China
Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05344729
- Locations
- 🇨🇳
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China
To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT05340530
- Locations
- 🇨🇳
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China
Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT05333276
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Nong Yang, Changsha, Hunan, China
A Phase II Clinical Trial of TQC3721 Suspension for Inhalation
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 460
- Registration Number
- NCT05292196
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jianxi, China
🇨🇳The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT05284994
- Locations
- 🇨🇳
Meizhou People's Hospital, Meizhou, Guangdong, China
🇨🇳Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05198531
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Guangxi Tumor Hospital, Nanning, Guangxi, China
🇨🇳Sun-Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05154630
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing Jishuitan Hospital, Beijing, Beijing, China
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 405
- Registration Number
- NCT05145218
- Locations
- 🇨🇳
AnYang Tumor Hospital, AnYang, Henan, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China